What Letrezol Actavis treats: main uses and benefits

Letrezol Actavis is a medication classified as an aromatase inhibitor. It is primarily used in the treatment of specific types of breast cancer in women who have gone through menopause. Its function is centered on managing hormone-sensitive conditions by influencing the way the body produces certain hormones.

Primary Uses

Letrezol Actavis is used in several clinical scenarios related to breast cancer management:

• Adjuvant Treatment: It is used as a first-line treatment for postmenopausal women with early-stage breast cancer that is hormone receptor-positive. The goal is to reduce the risk of the cancer returning after initial surgery.
• Extended Adjuvant Treatment: It may be prescribed for women who have already completed a standard course of treatment (such as tamoxifen) to provide further protection against recurrence.
• Advanced or Metastatic Cancer: The medication is used to treat breast cancer that has spread to other parts of the body or has progressed following other hormonal therapies.

How it Works

Many types of breast cancer are stimulated by estrogen, a female sex hormone. In postmenopausal women, although the ovaries no longer produce estrogen, the hormone is still created in other body tissues through the action of an enzyme called aromatase.

Letrezol Actavis works by inhibiting this enzyme, which significantly lowers the amount of estrogen circulating in the body. By reducing the estrogen levels, the medication helps to slow down or stop the growth of cancer cells that rely on this hormone to thrive.

Benefits of Treatment

The principal benefit of Letrezol Actavis is its role in hormone-responsive oncology. By effectively suppressing estrogen production, the medication offers:

• Reduced Risk of Recurrence: In early-stage cancer, it helps lower the statistical likelihood of the disease returning.
• Disease Control: In more advanced cases, it can help manage the size and spread of tumors, potentially leading to a period of disease stability.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who Can and Cannot Use Letrezol Actavis

The use of Letrezol Actavis (Letrozole) is restricted to specific patient populations as strictly defined by regulatory labeling.

---

Eligibility Scope

Classification	Eligible Population	Contraindicated Population
Primary Status	Postmenopausal women with confirmed Hormone Receptor Positive (HR+) status.	Premenopausal women (women of child-bearing potential).
Reproductive Status	Not applicable.	Pregnant women and Lactating/Breastfeeding women.

---

Age and Condition Limitations

Age-Related Rules: Use is not recommended in the pediatric population (children and adolescents) as safety and efficacy have not been established. No dosage adjustment is generally required for older adults (geriatric patients).

Condition-Specific Use:

• Severe Hepatic Impairment: Use is conditional. Patients with severe hepatic dysfunction require close supervision and a recommended dose reduction.
• Severe Renal Impairment: Use requires careful consideration as the medicine has not been investigated sufficiently in patients with creatinine clearance below 10 mL/min.
• Other Restrictions: Patients with a history of osteoporosis or hypercholesterolemia are eligible, but require required monitoring of bone mineral density or serum cholesterol.

Connection to Eligibility Profile: Official regulatory documents strictly define eligibility based on the required postmenopausal status and absolutely contraindicate the medicine for women of reproductive potential. Conditional use restrictions apply to patients with compromised organ function, ensuring adherence to the labeled safety profile.

Interactions with other medicines and products

This section outlines interactions with other medicinal products and conditions as documented in official government regulatory information.

Property	Description (Official Regulatory Statement)
Medicinal product categories with documented interactions	Estrogens, Selective Estrogen Receptor Modulators (SERMs), certain CYP enzyme inhibitors (e.g., Cimetidine), and anticoagulants (e.g., Warfarin).
Specific interacting medicines (if explicitly listed)	Tamoxifen and Estrogen-containing products are explicitly listed as subject to restrictions. Cimetidine and Warfarin were subjects of dedicated pharmacokinetic studies.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic interaction (change in plasma concentration/AUC) and Pharmacodynamic antagonism (with estrogens).
Timing-based interaction rules (if applicable)	The medication may be administered without regard to meals; no mandatory time separation from food is required.
Population-specific interaction notes (if applicable)	Systemic exposure is increased approximately two-fold in patients with severe hepatic impairment (liver cirrhosis). No clinically significant interaction was noted in patients with varying degrees of renal impairment.
Interaction-related restrictions	Contraindicated for co-administration with Tamoxifen and any Estrogen-containing products.

Interaction Severity Classification (High-Level)

• Contraindicated Combinations: Co-administration with Tamoxifen causes a documented 38% reduction in Letrozole plasma levels, compromising intended systemic exposure. The use of Estrogens causes pharmacodynamic antagonism of the drug’s action.
• Clinically Non-Significant: Pharmacokinetic studies with Cimetidine and Warfarin found no clinically significant effect on Letrozole's plasma concentrations, requiring no change to use restrictions.

Connection to the Overall Interaction Profile

The regulatory profile strictly mandates that co-administration with Tamoxifen and estrogen products is prohibited due to evidence of altered pharmacokinetics or therapeutic antagonism. The profile also formally documents the increase in systemic exposure in patients with severe hepatic impairment. These explicit constraints, combined with the documented absence of a clinically significant interaction with food, define the parameters for co-administration of other medicines and products.

Letrozole acts by exclusively targeting the enzyme system responsible for creating estrogen, leading to a sustained reduction of this key hormone throughout the body.

Targeted Blockade of the Aromatase Enzyme

This mechanism focuses on the aromatase enzyme (CYP19A1), the specific molecular structure that catalyzes the final, essential step in the body's synthesis of estrogens (like estradiol and estrone) from precursor androgens. Letrozole is a non-steroidal competitive inhibitor that binds reversibly to the enzyme's active site. This action inhibits the enzyme pathway, leading to a molecular cascade that restricts the production of the hormonal mediator.

Systemic Estrogen Deprivation and Pathway Selectivity

By blocking the aromatase enzyme, the drug severely restricts the conversion of androgens into estrogens primarily in peripheral extraglandular tissues (e.g., adipose tissue and muscle). This results in a sustained reduction of circulating estrogen, which is the central physiological consequence of the enzyme inhibition. The compound is highly selective for aromatase, resulting in no significant impact on the production of other adrenal steroids, such as cortisol and aldosterone.

Mechanistic Constraints

The drug's mechanism of action is closely tied to the physiological context, as it relies on the extraglandular aromatase being the dominant source of estrogen; the mechanism is functionally constrained if ovarian function is intact. Furthermore, the overall mechanistic consequence may be functionally limited if cells activate estrogen-independent signaling pathways that bypass the need for the hormonal stimulus.

Administration and Routine

Letrozole Actavis is an oral medication provided in tablet form. It is intended for long-term use as part of a therapeutic regimen. To maintain a consistent level of the medication in the body, it is recommended to take the tablet at the same time each day.

Practical Considerations

• Oral Intake: The tablet should be swallowed whole with a glass of water or another non-alcoholic liquid.
• Food Interaction: The medication can be taken regardless of food intake; it may be consumed either with a meal or on an empty stomach.
• Consistency: Establishing a daily routine helps ensure that the medication is integrated into the patient's schedule.

Duration of Use

The duration of use is determined based on individual clinical requirements and the specific goals of the treatment. Use typically continues for several years, provided the clinical benefit is maintained. If there are questions regarding how long the medication should be taken, consultation with a healthcare professional is appropriate.

Research evidence / Overview of studies for Letrezol Actavis

The available information about Letrezol Actavis (Letrozole) research is sourced from published clinical trials, including randomized studies, comparative research, and extended observation reports. This research was studied for use in various clinical situations, monitoring for measured changes in tumor size or disease-related events. The evidence described here is focused strictly on study structure and reported findings, not individual clinical decisions or treatment advice.

---

Evidence for Adjuvant (Post-Surgery) Treatment

Research examining the use of Letrozole following surgical intervention, known as adjuvant treatment, primarily relies on extensive, multi-center randomized controlled trials (RCTs). Studies monitored outcomes such as Disease-Free Survival (DFS) and Overall Survival (OS) in postmenopausal women with hormone receptor-positive early breast cancer. Findings describe patterns observed in the studies related to DFS across the different comparison groups. However, early follow-up analyses in some trials showed no clear statistical difference in Overall Survival between the studied groups. Limited information is available regarding measurements of bone health across the entire study period.

---

Evidence for Extended Adjuvant Treatment

Evidence for the continued administration of Letrozole after a patient has completed an initial course of hormonal treatment comes from specific Phase III trials. Studies reported data related to DFS and Distant Disease-Free Survival (DDFS), with measurements compared to the placebo arm. This research focused on postmenopausal women who were disease-free after initial therapy. A key data limitation is that patient movement between study arms in major trials resulted in a specific constraint for the analysis and interpretation of long-term Overall Survival.

---

Main Research Gaps and Areas of Uncertainty

Scientific reviews identify several areas where evidence is still emerging. While research consistently reports differences in time-to-event outcomes, achieving clear statistical differences in Overall Survival across all comparative settings has led to mixed findings. The duration of hormonal treatment (e.g., questions regarding continuing beyond the currently studied period) is a subject where comparative evidence is limited, and research is ongoing.

Key Studies & References

1. Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer (BIG 1-98) - Adjuvant Monotherapy and Sequential Treatment
2. Letrozole versus Tamoxifen as First-Line Treatment for Metastatic Breast Cancer
3. Early and advanced breast cancer: diagnosis and management - NICE Guideline

Common questions about Letrezol Actavis (FAQ)

Q: Is Letrezol Actavis considered a type of chemotherapy treatment?

Official documentation classifies Letrozole as a hormone therapy drug and an antineoplastic agent (anti-cancer medicine), and specifically a third-generation aromatase inhibitor. The drug works by adjusting hormone levels in the body, which is a mechanism functionally distinct from traditional cytotoxic chemotherapy.

Q: How does the action of Letrezol Actavis differ from that of Tamoxifen?

Regulatory documents state that Letrozole is a non-steroidal aromatase inhibitor that works to significantly lower estrogen levels. In contrast, Tamoxifen is classified as a Selective Estrogen Receptor Modulator (SERM).

These two types of medicines operate through different mechanisms of action to achieve a therapeutic effect.

Q: What are the typical long-term expectations for a patient using Letrezol Actavis?

Studies and official information indicate that long-term use is associated with measured clinical outcomes. Research evidence focuses on measured outcomes such as Disease-Free Survival (DFS) and Overall Survival (OS), which help assess the medication’s therapeutic effects over an extended period in large-scale studies.

Q: Can men be prescribed Letrezol Actavis for any condition, according to labeling?

The regulatory label provides specific indications for the treatment of postmenopausal women with breast cancer. The current official labeling does not include indications for use in men for any condition.

Q: Can Letrezol Actavis cause mood changes or depression?

The official adverse reaction profile lists depression as an uncommon side effect of the medicine. The profile also includes anxiety as an uncommon event.

This means that mood changes are documented as possible effects of the medicine.

Q: How is the effectiveness of Letrezol Actavis generally assessed in clinical settings?

The effectiveness of the medicine is related to its therapeutic goal, which is to interrupt the hormone-dependent pathway.

In the clinical setting, assessment generally focuses on monitoring for specific outcomes such as preventing cancer recurrence or slowing disease progression, based on these goals.

Q: What is the difference between Letrezol and the brand name Letrezol Actavis?

Letrozole is the name of the active ingredient, which is the substance that produces the medicinal effect. Letrezol Actavis is a specific brand name under which the medicine containing the active ingredient letrozole is sold.

Q: How long does it usually take for Letrezol Actavis to start showing its intended effect in the body?

Pharmacokinetic data from official documents indicate how the medicine behaves in the body.

Based on this information, steady-state plasma concentrations of the active substance are generally reached after two to six weeks of daily dosing.

Q: Are there any official restrictions on driving or operating machinery while on Letrezol Actavis?

Official documents state that patients who experience these specific effects, such as fatigue or dizziness, may have an impaired ability to drive or operate machinery.

Q: Is Letrezol Actavis available as a generic drug?

The active ingredient, Letrozole, is generally available from multiple manufacturers under its generic name. It is also available under various brand names, including Letrezol Actavis.

Q: What does the official patient information recommend if a serious side effect occurs?

The official patient labeling describes seeking immediate medical attention or contacting the healthcare provider right away as the necessary action if any serious symptoms or adverse reactions are suspected.

Q: How does the drug's purpose relate to hormone receptors?

The drug is formally indicated for the treatment of hormone receptor-positive breast cancer. Its function is to lower the level of the hormone, estrogen, which is known to stimulate these receptors.

Q: What is the reported half-life of Letrezol Actavis in official pharmacological documents?

Pharmacological documents report that the terminal elimination half-life of the active ingredient is approximately 2 days (ranging from 2 to 4 days). This timeframe describes how long it takes for the concentration of the medicine in the body to be reduced by half.

Q: What is the significance of the 'Actavis' part of the drug name?

'Actavis' refers to the name of the pharmaceutical manufacturer or the company that holds the marketing authorization for this specific brand of the medicine.

Q: Can the medication affect vision or cause blurry sight?

The adverse reaction profile includes visual impairment reports. These have included side effects such as blurred vision and cataract as uncommon events.

Q: What is the maximum dose of Letrezol Actavis studied in clinical trials?

Official documentation on overdose states that single doses up to 32 mg have been studied in healthy volunteers, and up to 100 mg has been given to patients. No serious adverse effects were reported from these doses in the studies.

Q: Where can a patient find the full official Patient Information Leaflet (PIL) for Letrezol Actavis?

Official patient information leaflets (PILs) or FDA-approved Patient Package Inserts are typically located on the websites of the national regulatory agency that authorized the medicine in that region.

Q: What should be done if an overdose of Letrezol Actavis is suspected?

The official guidance advises that treatment of a suspected overdose should be symptomatic and supportive. It does not specify or suggest any particular management procedures beyond this general approach.

The storage and disposal of Letrozole tablets (Letrezol Actavis) must strictly follow official regulatory requirements to ensure product stability and safety.

Official Storage Conditions

Letrozole tablets must be stored at Controlled Room Temperature, which is maintained between 20 C and 25 C (68 F and 77 F). The medicine must be kept in the original container and the container must remain tightly closed to protect the tablets from moisture.

• Child Safety: The product must be stored out of the sight and reach of children.

Disposal Requirements

Official disposal guidance recommends using a medicine take-back program for unused or expired tablets. The tablets must not be flushed down a toilet or poured into a drain to prevent environmental contamination.